Coluracetam is a nootropic compound belonging to the racetam family. It was initially developed by Mitsubishi Tanabe Pharma Corporation for the treatment of Alzheimer’s disease but later investigated for its potential in addressing major depressive disorder (MDD) and generalized anxiety disorder (GAD).
Coluracetam enhances high-affinity choline uptake (HACU), a rate-limiting step in acetylcholine synthesis, which may contribute to its cognitive-enhancing effects. Preclinical studies suggest it improves memory deficits and cognitive impairments in animal models.
Coluracetam is structurally related to piracetam but features additional fluoroquinolone components. Its legal status varies by region, with some countries classifying it as a prescription-only substance.
The above informationis displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.
Sources:
https://en.wikipedia.org/wiki/Coluracetam
https://pubchem.ncbi.nlm.nih.gov/compound/214346
https://www.medchemexpress.com/Coluracetam.html
https://www.medkoo.com/products/11491
https://psychonautwiki.org/wiki/Coluracetam
https://www.nutrahacker.com/journal_club/en/coluracetam.php